Maze Therapeutics (NASDAQ:MAZE) Releases Earnings Results

Maze Therapeutics (NASDAQ:MAZE) announced its quarterly earnings data on Thursday. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.08, Zacks reports.

Maze Therapeutics Trading Down 5.0%

NASDAQ MAZE traded down $1.49 during trading hours on Friday, reaching $28.14. 80,753 shares of the company’s stock were exchanged, compared to its average volume of 299,937. The firm has a fifty day moving average of $25.57 and a 200-day moving average of $17.07. Maze Therapeutics has a one year low of $6.71 and a one year high of $34.29. The stock has a market cap of $1.23 billion and a PE ratio of -1.39.

Insider Buying and Selling

In other Maze Therapeutics news, Director Richard H. Scheller sold 20,744 shares of the business’s stock in a transaction on Monday, September 15th. The stock was sold at an average price of $22.37, for a total value of $464,043.28. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in Maze Therapeutics by 218.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock worth $34,615,000 after acquiring an additional 915,342 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Maze Therapeutics by 80.7% during the third quarter. JPMorgan Chase & Co. now owns 7,890 shares of the company’s stock valued at $205,000 after purchasing an additional 3,524 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Maze Therapeutics by 452.5% in the second quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company’s stock valued at $57,000 after purchasing an additional 3,774 shares in the last quarter. Engineers Gate Manager LP bought a new position in Maze Therapeutics in the 2nd quarter worth approximately $125,000. Finally, Bank of America Corp DE lifted its holdings in Maze Therapeutics by 33.6% during the 2nd quarter. Bank of America Corp DE now owns 5,782 shares of the company’s stock worth $71,000 after buying an additional 1,455 shares in the last quarter.

Analyst Upgrades and Downgrades

MAZE has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Maze Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. JPMorgan Chase & Co. lifted their target price on shares of Maze Therapeutics from $27.00 to $37.00 and gave the company an “overweight” rating in a research report on Monday, September 29th. BTIG Research increased their price target on shares of Maze Therapeutics from $30.00 to $37.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. Finally, Guggenheim raised their price target on shares of Maze Therapeutics from $19.00 to $34.00 and gave the stock a “buy” rating in a research note on Monday, September 15th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Maze Therapeutics currently has an average rating of “Buy” and an average price target of $37.00.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.